Unique ID issued by UMIN | C000000076 |
---|---|
Receipt number | R000000125 |
Scientific Title | A prospective open-randomized controlled trial comparing postoperative chemoradiotherapy versus chemotherapy for cervical cancer patients with lymph node metastases. |
Date of disclosure of the study information | 2010/04/01 |
Last modified on | 2005/08/24 15:54:12 |
A prospective open-randomized controlled trial comparing postoperative chemoradiotherapy versus chemotherapy for cervical cancer patients with lymph node metastases.
Postoperative radiotherapy for cervical cancer.
A prospective open-randomized controlled trial comparing postoperative chemoradiotherapy versus chemotherapy for cervical cancer patients with lymph node metastases.
Postoperative radiotherapy for cervical cancer.
Japan |
Patients who had radical hysterectomy for stage IB-IIB cervical cancer, and were certified to have lymph node mestastases histologocally after radical surgery. Patients with only squamous cell carcinoma were eligible.
Obstetrics and Gynecology | Radiology |
Malignancy
NO
The purpose of this study is to clarify the efficiency of concurrent chemoradiotherapy (group A) and chemotherapy (Group B) for paitents with lymph node metastases from cervical cancer. Patients are randomized to group A or B after radical surgery.
Efficacy
Confirmatory
Pragmatic
Phase II,III
Recurrent rata including distant metastases.
Late adverse effect
Survival
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as adjustment factor in dynamic allocation.
NO
Pseudo-randomization
2
Treatment
Maneuver |
Concurrent chemoradiotherapy (Group A)
Whole pelvic irradiation (50 Gy) and
CDDP 70mg/m2, each 4 week, 3 times.
Chemotherapy (Group B)
CDDP 70mg/m2, each 4 week, 3 times.
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1. squamous cell carcinoma of the cervix and clinical stage IB-IIB.
2. radical hysterectomy was performed.
3. with histologically certified lymph node metastases.
4. no abnormal findings in laboratory tests.
5. PS is between 0-2.
6. Age is between 20-75.
7. No chemotherapy for other cancer (except cervical cancer) within recent 3 months.
1. Past history of pelvic surgery (except appendectomy).
2. past history of pelvic irradiation.
3. Positive surgical margin, or positive paraaortic lymph nodes.
4. Estimaated survival is less than 6 months.
5. Renal dysfunction.
6. Acitve infection (Tuberculosis or mycosis) in the pelvis.
7. Active double cancer.
8. Otehr reasons that is not eligible to this trial.
170
1st name | |
Middle name | |
Last name | Hisao Ito, M.D. |
Chiba University, Graduate School of Medicine,
Department of Radiology
1-8-1 Inohana, Chuoku, Chiba City, 260-8670, Japan
043-226-2099
1st name | |
Middle name | |
Last name | Takahsi Uno, M.D. |
Chiba University, Graduate School of Medicine,
Department of Radiology
1-8-1 Inohana, Chuoku, Chiba City, 260-8670, Japan
043-226-2100
unotakas@faculty.chiba-u.jp
Study Group of Postoperative radiotherapy for cervical cancer.
Grant of Ministry of Health, Labour and Welfare
Japan
none
none
NO
2010 | Year | 04 | Month | 01 | Day |
Unpublished
2005 | Year | 01 | Month | 10 | Day |
2005 | Year | 02 | Month | 01 | Day |
2010 | Year | 04 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2012 | Year | 04 | Month | 01 | Day |
2012 | Year | 07 | Month | 01 | Day |
2005 | Year | 08 | Month | 24 | Day |
2005 | Year | 08 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000125